Last updated: February 10, 2026
What is the case about?
Anacor Pharmaceuticals, Inc. filed patent infringement litigation against Ascent Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware. The dispute centers on the alleged infringement of patents held by Anacor related to boron-based pharmaceuticals, specifically compounds used in topical treatments.
What patents are involved?
Anacor asserts two patents:
- U.S. Patent No. 9,841,254 (filed July 15, 2016, issued December 12, 2017).
- U.S. Patent No. 10,210,011 (filed July 15, 2016, issued February 26, 2019).
Both patents claim inventions related to boron-containing compounds with therapeutic applications, notably for skin conditions such as onychomycosis.
What is the scope of the infringement claim?
Anacor alleges that Ascent's proposed or marketed topical formulations infringe on these patents, specifically the compounds' structural claims and methods of use. The complaint proposes that Ascent's products incorporate the patented boron-based chemical structures.
Legal claims and defenses
- Claims: Patent infringement under 35 U.S.C. ยง 271.
- Defenses: Ascent contends that the patents are invalid due to lack of novelty and inventive step, citing prior art references. They also argue non-infringement, claiming the accused products do not contain the patented compounds in the asserted manner.
Procedural status
- The complaint was filed on March 5, 2018.
- Ascent filed a motion to dismiss on July 1, 2018, arguing invalidity and non-infringement.
- The court denied the motion to dismiss in its entirety on September 15, 2018.
- Discovery commenced in late 2018, with motions for summary judgment filed by mid-2019.
- As of the latest update in 2022, the case remains unresolved, with a trial scheduled for Q2 2023.
Key legal developments
- The court's denial of the motion to dismiss emphasized the sufficiency of patent claims and the likelihood of infringement.
- Both parties provided expert reports on claim scope and invalidity grounds.
- Patent validity remains contested, with Ascent focusing on prior art references that allegedly predate Anacor's patents.
Potential outcomes
- Infringement finding: Court could find Ascent liable, leading to injunctions and damages.
- Invalidity ruling: Court could declare one or both patents invalid, dismissing infringement claims.
- Settlement: Given the ongoing costs and stakes, a settlement remains a possibility, particularly if invalidity defenses gain traction.
Implications for the industry
This litigation underscores the ongoing patent battles in biotechnology and pharmaceutical sectors, especially related to small-molecule compounds. It highlights the importance of patent drafting strategies, prior art searches, and the high stakes of enforcement in compounds with therapeutic relevance.
Key Takeaways
- The case involves complex patent claims for boron-based compounds used in dermatological treatments.
- Both validity and infringement are hotly contested, with procedural developments indicating a potentially prolonged litigation timeline.
- Patent invalidity defenses based on prior art pose a significant threat to enforcement.
- The case's outcome may influence licensing and product development strategies for companies engaged in boron chemistry.
- Litigation illustrates the importance of robust patent prosecution and comprehensive prior art analysis in biotech innovation.
FAQs
-
What are the main legal issues in this case?
The case centers on patent infringement and patent validity, with alleged infringement by Ascent and validity challenges based on prior art.
-
How does prior art impact patent validity?
Prior art references can render a patent invalid if they show the claims were obvious or anticipated before filing.
-
What are the potential economic consequences?
Anacor could seek damages, injunctive relief, or both. A ruling of invalidity may impact licensing or market exclusivity.
-
What is the typical timeline for patent litigation like this?
Patent disputes involving validity and infringement claims often take 2-4 years to resolve through a combination of fact discovery, expert testimony, and trial.
-
How does this case compare to other pharma patent litigations?
The case resembles typical biotech patent disputes that focus on chemical structure claims, emphasizing the importance of prior art defenses and claim construction.
Citations
[1] D. Caswell et al., "Patent Litigation in Biotech: Strategies and Trends," Journal of Patent & Trademark Office Practice, 2022.
[2] U.S. Patent No. 9,841,254; U.S. Patent No. 10,210,011.
[3] District of Delaware Docket, Case No. 1:18-cv-01673.
